OBJECTIVES: In contrast to lung cancer with ground-glass opacity, the radiological investigation of solid lung cancer has not been well examined. The aim of this study was to explore chest computed tomography (CT) and positron emission tomography (PET)/CT findings with regard to outcomes after lung cancer surgery in order to radiologically classify clinical stage IA lung cancers by tumour aggressiveness.
INTRODUCTION
Since chest computed tomography (CT) tends to detect small-sized lung cancers, the outcome for lung cancer could be improved with proper treatment. Based on these findings, the concept of limited resection for small-sized lung cancers should be considered. Even though the indications for limited resection in patients with earlystage lung cancer might be appropriate, the precise results of limited resection remain controversial [1] [2] [3] [4] . To improve survival after surgery, a preoperative diagnosis of aggressive lung cancer and selection of adequate surgical procedures are needed.
With respect to ground-glass opacity (GGO), a relationship between thin-section CT appearance and tumour characteristics has been well investigated [5, 6] . Despite a strong understanding of lung cancer with GGO (i.e. with non-solid density), lung cancer with solid density has not yet been clarified. Tsutani et al. [7] revealed that the solid diameter of the lung nodule is a much more effective marker for detecting aggressive lung cancer. However, in the case of solid lung cancers, chest CT cannot reveal the characteristics of the solid nodules. Therefore, an alternative approach is needed.
The role of positron emission tomography (PET)/CT in clinical practice for lung cancer has been established [8] [9] [10] [11] [12] [13] [14] [15] [16] . The standardized uptake value (SUV) is usually used as a prognostic factor. However, because it is affected by blood sugar levels, body weight and the PET/CT protocol, it is generally recognized that SUV is a fluctuating value. Therefore, we revealed that the SUV index is a more standardized value than single SUV max and showed the effectiveness of PET/CT for detecting less aggressive tumours of stage I non-small-cell lung cancer (NSCLC) [17, 18] . However, we did not examine these tumours using the CT findings.
The aim of this study was to explore chest CT and PET/CT findings as they relate to outcomes after lung cancer surgery in order to radiologically classify clinical stage IA lung cancers. We considered the potential application of this radiological classification for selection of adequate surgical procedures for clinical stage IA lung cancers.
PATIENTS AND METHODS
The institutional ethics committee approved this study and waived the requirement for informed consent from patients, since the patient data remained anonymous.
Patients
We collected the patient data prospectively from May 2004. At the time of diagnosis, data were collected regarding age, gender, smoking status, comorbidities, tumour markers, including the serum carcinoembryonic antigen (CEA) level, timing of surgery, maximum tumour size, characteristics of the nodules, clinical TNM stage (7th edition) [19] , chest CT findings, SUV max , right lobe of the liver SUV mean , extent of surgery, pathological findings, time to recurrence, time to last follow-up, time to death and cause of death. The patient prospective lung cancer database that had been presented in our previous reports [17, 18] was updated monthly, and we used the data from this database. Retrospective analysis was performed from May 2004 to March 2013. Eligibility criteria for this study included: (i) clinical stage IA, (ii) curativeintent resection, (iii) no induction therapy, (iv) preoperative thinsection CT, (v) preoperative PET-CT, (vi) the absence of severe liver disease (i.e. liver cirrhosis), (vii) the absence of severe diabetes, (viii) the absence of multiple lung cancers and (ix) written informed consent for surgery. During the study period, 716 patients underwent lung cancer surgery. After exclusion of those cases who did not fulfill the enrolment criteria, 315 clinical stage IA patients were evaluated. We included those with pure GGO or subcentimetre lung nodules.
Computed tomography and positron emission tomography/computed tomography protocol CT scans were performed on Aquilion ONE systems (Toshiba Medical Systems, Tochigi, Japan) and on Lightspeed VCT (General Electric, Milwaukee, WI, USA). The scanning parameters included a tube voltage of 120 kV, a tube current of 100-400 mA and a pitch of 0.028 for the Aquilion ONE and 1.3 for the Lightspeed VCT. Thin-section images were reconstructed with 0.5-mm thickness and 0.5-mm reconstruction intervals.
Since evaluation of the GGO size or area is dependent on the observer, there is concern about such evaluations. Therefore, in this study, CT findings were simply classified as solid or non-solid. Solid nodules were defined as those that completely obscure the lung parenchyma. Non-solid nodules included both GGO and solid components. GGOs are defined as focal nodular areas of increased lung density through which normal parenchymal structures, such as the bronchus and vessels, can be recognized [20] . Non-solid nodules included the pure GGO and mixed GGO nodules.
The routine PET/CT protocol and the calculation for SUV have been described in our previous publications [17, 18] . A standard dose of 3.75 MBq/kg F-18 fluorodeoxyglucose (FDG) was administered intravenously, and PET and CT images were scanned 60 min later on a Discovery LS instrument (General Electric) or a Biograph mCT (Siemens, München, Germany). The corrected SUV, which was defined as the SUV index, was calculated as the ratio of tumour SUV max to liver SUV mean . Namely, after the tumour SUV max was calculated, regions of interest (ROIs) were designed as circular, and the right liver lobe ROI diameters were 60 mm ( Fig. 1) [17, 18, 21] . We set the cut-off value of the SUV index to 1.0, because our previous data showed that the patients with an SUV index <1.0 did not develop recurrence [18] .
Pathological diagnosis
Pathological diagnosis was performed in a routine fashion. To evaluate lymphovascular and pleural invasion, these sections were stained with Elastica-Masson reagents. In this study, invasive lung cancer was defined by lymph node metastasis, lymphovascular invasion or pleural invasion. For the classification of adenocarcinoma, we used the new IASLC/ATS/ERS lung adenocarcinoma classification [2] .
Surgery
We perform lobectomy as a standard procedure; however, sublobar resection was used in the patients with clinical stage T1a, high GGO ratios or severe comorbidities. Mediastinal lymph node dissection was used in a standard fashion; however, we performed selective lymph node dissection depending on the T factor, GGO ratio or patient comorbidities. 
Follow-up
Patients with pathological stage IB or higher cancers received chemotherapy. Postoperative follow-up was performed by thoracic surgeons every 3-4 months over 5 years. A routine follow-up consisted of chest X-rays, a physical examination and blood chemistry tests, including tumour marker analysis. Chest and brain CTs were performed annually. If patients complained of symptoms or if tumour markers were significantly elevated, additional examinations were performed.
Statistical analysis
Overall survival, cancer-specific survival and recurrence-free (RF) rates were analysed using the Kaplan-Meier method, and differences in variables were evaluated using the log-rank test. Survival or recurrence periods were measured from the date of surgery. For both the cancer-specific survival and the RF rates, patients who survived or died without evidence of recurrence were censored.
Cox proportional hazards regression analysis was used for uniand multivariate analyses to identify the prognostic factors for overall survival. The data were analysed using version 5.0.1 of the JMP software package (SAS Institute, Inc., Cary, NC, USA). A P-value of <0.05 was considered statistically significant.
RESULTS
Patient characteristics are summarized in Table 1 . Liver SUV mean measurements ranged from 1.4 to 3.0 (median, 2.2; mean ± SD, 2.2 ± 0.3). Approximately 80% of tumours were adenocarcinomas, and 74 of 315 (23.5%) patients were diagnosed with pathological invasive lung cancer. One patient underwent a left pneumonectomy because of unexpected lymph node metastasis in the hilum and mediastinum. Thirty-seven patients received adjuvant chemotherapy after surgery. The median follow-up time for the surviving patients was 31 (range, 0-102) months. Two (0.6%) patients died from postoperative complications: sepsis after 47 days in 1 patient and pneumonia after 48 days in the second. During the follow-up period, 43 (13.7%) patients died; of whom, 22 (7.0%) died from lung cancer, 8 (2.5%) from other malignancies, 2 (0.6%) from respiratory disease, 2 (0.6%) from cerebrovascular disease and 7 from other causes. During that period, 41 (13.0%) patients developed recurrence after surgery. Sites of recurrence included mediastinal and hilar lymph nodes (n = 14), lung (n = 12), bone (n = 9), pleuritis carcinomatosa (n = 7), brain (n = 5), liver (n = 2), meningitis carcinomatosa (n = 1) and adrenal gland (n = 1). Regarding limited resection, with segmentectomy, 1 patient experienced hilar lymph node recurrence, while with wedge resection, 1 patient experienced surgical stump recurrence and 4 patients intrathoracic lymph node recurrence.
According to the SUV index of PET/CT and CT findings, these patients were divided into four groups (Fig. 2) . Group A (n = 84, 26.7%) had an SUV index <1.0 and non-solid tumours (Fig. 2) , Group B (n = 24, 7.6%) had an SUV index <1.0 and solid tumours (Fig. 2) , Group C (n = 54, 17.1%) had an SUV index ≥1.0 and nonsolid tumours (Fig. 2) and Group D (n = 153, 48.6%) had an SUV index ≥1.0 and solid tumours (Fig. 2) .
In the pathological examination, there were 261 adenocarcinoma cases, which included adenocarcinoma in situ (n = 35), minimally invasive adenocarcinoma (n = 44) and invasive adenocarcinoma (n = 176) [2] . When the pathological factors were examined in each group, there was a trend of the invasive factor ratios significantly increasing from Group A to D (Table 2 ). Invasive lung cancer was found in 2/84 (2.4%) patients in Group A, 1/24 (4.2%) in B, 13/54 (24.1%) in C and 58/153 (37.9%) in D; the ratio increased with the progression in radiological findings (P < 0.01). 
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The 5-year overall survival, 5-year cancer-specific survival and 5-year RF rates were 80.2, 89.7 and 80.9%, respectively. According to CT findings, when we compared survival and recurrence in patients with solid versus non-solid tumours, the 5-year overall survival rates were 86.8 vs 75.1%, respectively (P < 0.01); the 5-year cancer-specific survival rates were 97.3 vs 83.5% (P < 0.01) and the 5-year RF rates 95.7 vs 69.0% (P < 0.01), respectively.
Kaplan-Meier curves were generated for the four groups. The overall survival rate was 94.0% in Group A, 90.9% in B, 79.6% in C and 73.5% in D (P < 0.01) (Fig. 3 ). There were no significant differences in overall survival in Groups A vs B (P = 0.46), B vs C (P = 0.52), B vs D (P = 0.16) or C vs D (P = 0.19). There were significant differences in Groups A vs C (P = 0.03) and A vs D (P < 0.01). The cancer-specific survival rate was 100% in both Groups A and B, 94.6% in C and 81.7% in D (Fig. 4) . For cancer-specific survival, there were no significant differences in Groups A and B vs C (P = 0.169) and C vs D (P = 0.07). There was a significant difference in A and B vs D (P < 0.01). The 5-year RF rate was 100% in Groups A and B, 90.3% in C and 65.7% in D. There was a significant difference in the 5-year RF in Groups A and B vs C (P = 0.04) and in A and B vs D (P < 0.01). Group C had less frequent recurrence than did Group D (P < 0.01) (Fig. 5 ). There were no patients in Groups A or B who died from lung cancers or who developed recurrence. Regarding overall survival, univariate analysis showed that male gender, age, high CEA, clinical T1b, high SUV index and solid CT findings were prognostic factors. Multivariate analysis also showed that male gender, age, clinical T1b and high SUV index were significant prognostic factors (Table 3) . After exclusion of minimally invasive adenocarcinoma or adenocarcinoma in situ cases, which have good prognosis, an SUV index <1.0 became a significant prognostic factor in univariate analysis (P < 0.01) and a marginal factor in multivariate analysis (P = 0.05). 
DISCUSSION
CT evaluation of lung cancer with vast GGO provided useful information for detecting non-invasive adenocarcinoma [5, 6] . Suzuki et al. [5] showed that when the ratio of consolidation to tumour size is used for evaluation, pathological non-invasiveness can significantly be correlated with radiological non-invasiveness. Asamura et al. [6] demonstrated that a consolidation to a tumour ratio ≤0.25 in GGO cT1a tumours indicates an excellent prognosis before surgery for the patient. However, because measurement of the GGO size or area is dependent on the observer, there is concern about the evaluation of GGO. It is possible that calculation of the GGO ratio differs among clinicians. In contrast to GGO, which indicates the non-solid part of the tumour, consolidation, or the solid part, is recognized as invasive lung cancer. Tsutani et al. [7] showed that clinical stage IA lung adenocarcinoma depends on the CT findings. When compared with mixed tumours, solid tumours were significantly associated with lymphovascular invasion, pleural invasion, lymph node metastasis and poor prognosis [7] . Non-solid lung cancers with GGO have been well explored, but the behaviours of solid lung cancer have not been clarified. Therefore, this study divided lung cancers into two categories, non-solid versus solid. Many studies support the utility of PET for determining the prognosis [8] [9] [10] [11] [12] [13] [14] [15] [16] of lung cancer. Even though SUV determination is probably the most widely used method for evaluating lung cancer patients, there are some objections to using SUV. The SUV determined by PET/CT is affected by various parameters [22, 23] : patient characteristics, blood sugar levels, instrumentation, PET protocols, analytic software and different radiologists across institutions. On the other hand, Weiss and Korn [23] stated that, for the measure of quality control, it may be useful to record the liver SUV of the patient each time a PET study is performed. Since the liver SUV has been reported previously to be consistent among patients [24] , we used the liver SUV as an internal control to correct for tumour SUV, according to a previous study [21] . The liver SUV is easily obtained for ROI determination, and the SUV index can be readily available. Since the present study excluded patients with severe hepatic disorders, the effect of liver disease on liver SUV is not known. In the present study, the SUV index was a useful marker, especially when used together with thin-section CT findings, to evaluate a tumour's biological aggressiveness and prognosis.
Recently, a group investigated 610 clinical stage IA adenocarcinoma patients using SUV max and GGO on high-resolution CT [25] . They demonstrated that optimal SUV max and GGO ratio cut-offs for predicting recurrence were 2.9 and 25%, respectively. They also revealed that the cut-off was significantly related to tumour aggressiveness, survival and recurrence [25] . Our study has demonstrated that the SUV index is a much more convenient predictive marker of recurrence or invasiveness for patients with early-stage NSCLC. PET can show the tumour biological characteristics using FDG uptake, while CT can only depict the anatomical features of a tumour. A combination of PET/CT with thin-section CT can better distinguish the non-invasive lung cancer patients who would benefit from limited resection.
There are some limitations to our study. First, the determination of the SUV index cut-off value needs further investigation for clinical practice. The present study was based on our previous studies, which showed that there were no relapsed lung cancer cases with an SUV index <1.0 [17, 18] . To select a patient with non-invasive lung cancer, this cut-off value might be too strict, and some patients would suffer from excessive surgery as a result. However, using a strict cut-off value can reduce the risk of recurrence as best as possible. Secondly, because of the technological limitation of PET/CT, the interpretation of PET/CT findings in subcentimetre lung cancers might be inaccurate. The present study included five subcentimetre nodule cases. We consider that small nodules should be evaluated by thin-section CT and PET/CT. Thirdly, the present study was single institutional with a short follow-up duration, and the statistical power might not have been sufficient. For early lung cancers, in particular, long-term follow-up is needed. In addition, 48 of 315 cases (15.2%) did not undergo lymph node dissection due to wedge resection. We need more robust evidence; therefore, we plan to launch prospective multi-institutional studies to validate the results of the present study.
In conclusion, subcentimetre non-solid nodules should be evaluated using thin-section CT, and our results suggest that preoperative PET/CT and thin-section CT findings provide important information for a selection of surgical procedures for clinical stage IA lung cancers. The results of this study demonstrated the patients' prognosis only. To apply these results to limited resection for lung cancer patients, more investigations and clinical trials will be necessary. In clinical stage IA lung cancers displaying solid or non-solid density in thin-section findings, an SUV index <1.0 may be a better criterion for detecting non-aggressive lung cancer.
